The DOI matches its Crossref record, with a small difference in title or year; 22 of the 22 references it cites were found in a registry or an index.
Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive Therapy
Open accessAbstract
BACKGROUND: Among patients with type 1 diabetes mellitus, intensive therapy (with the aim of achieving near-normal blood glucose and glycosylated hemoglobin concentrations [hemoglobin A1c]) markedly reduces the risk of microvascular complications as compared with conventional therapy. To assess whether these benefits persist, we compared the effects of former and intensive conventional therapy on the recurrence and severity of retinopathy and nephropathy for four years after the end of the Diabetes Control and Complications Trial (DCCT). METHODS: At the end of the DCCT, the patients in the conventional-therapy group were offered intensive therapy, and the care of all patients was transferred to their own physicians. Retinopathy was evaluated on the basis of centrally graded fundus photographs in 1208 patients during the fourth year after the DCCT ended, and nephropathy was evaluated on the basis of urine specimens obtained from 1302 patients during the third or fourth year, approximately half of whom were from each treatment group. RESULTS: The difference in the median glycosylated hemoglobin values between the conventional-therapy and intensive-therapy groups during the 6.5 years of the DCCT (average, 9.1 percent and 7.2 percent, respectively) narrowed during follow-up (median during 4 years, 8.2 percent and 7.9 percent, respectively, P<0.001). Nevertheless, the proportion of patients who had worsening retinopathy, including proliferative retinopathy, macular edema, and the need for laser therapy, was lower in the intensive-therapy group than in the conventional-therapy group (odds reduction, 72 percent to 87 percent, P<0.001). The proportion of patients with an increase in urinary albumin excretion was significantly lower in the intensive-therapy group. CONCLUSIONS: The reduction in the risk of progressive retinopathy and nephropathy resulting from intensive therapy in patients with type 1 diabetes persists for at least four years, despite increasing hyperglycemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The potential risks of intensive glycemic control may be obviated by incorporating agents that are not associated with hypoglycemia, especially in persons with frequent severe hypoglycemia, hypoglycemia unawareness, or a very long duration of DM, and particularly in the presence of established and advanced atherosclerosis, advanced age, and terminal illness.69,70,76–81”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [77]
In the citing paper
“Follow-up of the DCCT cohorts in the Epidemiology of Diabetes Interventions and Complications (EDIC) study (44,45) demonstrated persistence of these microvascular benefits over two decades despite the fact that the glycemic separation between the treatment groups diminished and disappeared during follow-up.”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [44]
In the citing paper
“Both DCCT/EDIC and UKPDS suggested that there is metabolic memory, or a legacy effect, in which a finite period of intensive glucose lowering yielded benefits that extended for decades after that period ended (44-48).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [44]
In the citing paper
“Follow-up of the DCCT cohorts in the Epidemiology of Diabetes Interventions and Complications (EDIC) study (42,43) demonstrated persistence of these microvascular benefits over two decades despite the fact that the glycemic separation between the treatment groups diminished and disappeared during follow-up.”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [43]
In the citing paper
“Follow-up of the DCCT cohorts in the Epidemiology of Diabetes Interventions and Complications (EDIC) study has shown persistence of this effect in previously intensively treated subjects, even though their glycemic control has been equivalent to that of previous standard arm subjects during follow-up (46,47).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [46]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Self-citationPrediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Hapeman, D. E. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,373
(1985) · Archives of Ophthalmology · doi:10.1001/archopht.1985.01050120030015 · Cited by 2,540
The Diabetes Control and Complications Trial Research Group (1995) · Diabetes · doi:10.2337/diab.44.8.968 · Cited by 1,301
Self-citationVlassara, H., Bucala, R., & Striker, L. J. (1994) · PubMed · Cited by 848
Fundus Photographic Risk Factors for Progression of Diabetic Retinopathy
(1991) · Ophthalmology · doi:10.1016/s0161-6420(13)38014-2 · Cited by 814
Diabetes Control and Complications Trial (DCCT) Research Group (1996) · Diabetes · doi:10.2337/diab.45.10.1289 · Cited by 597
Research works printed but not linked: 2
- Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames: Iowa State University Press, 1980.
- Vlassara H, 1994, Lab Invest, 70, 138
Cited by
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Self-citationStandards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Metadata
- Authors
- The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group
- Corresponding author
- The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2000-02-10
- Volume
- 342
- Issue
- 6
- Pages
- 381-389
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2630213
- OpenAlex
- W2760585829
- Cited by
- 1,534
- References
- 20
- Citations by year
- 2026: 21 · 2025: 31 · 2024: 39 · 2023: 29 · 2022: 37 · 2021: 38 · 2020: 47 · 2019: 39 · 2018: 47 · 2017: 54 · 2016: 64 · 2015: 77 · 2014: 78 · 2013: 61 · 2012: 59
- FWCI
- 41.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (n01dk062204-003)
- National Institute of Diabetes and Digestive and Kidney Diseases (N01 DK062204)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- type 1 diabetes, intensive insulin therapy, glycemic control, retinopathy, diabetic nephropathy, microvascular complications, diabetic retinopathy progression, proliferative retinopathy, macular edema, laser photocoagulation, urinary albumin excretion, HbA1c, Diabetes Control and Complications Trial, long-term follow-up
- MeSH terms
- Adolescent, Adult, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Diabetic Retinopathy, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Insulin, Male, Regression Analysis, Risk, Severity of Illness Index, Incidence, Randomized Controlled Trials as Topic, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive Therapy. https://app.cochat.ai/papers/10.1056/nejm200002103420603
- The paper
- The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. (2000). Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive Therapy. New England Journal of Medicine. https://doi.org/10.1056/nejm200002103420603
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.